trending Market Intelligence /marketintelligence/en/news-insights/trending/SODBI-inkoEEK_EsCcO8NA2 content esgSubNav
In This List

US FDA grants pediatric exclusivity to AstraZeneca's asthma inhaler

Blog

Global Capital Markets & SPAC Activity – H1 2021

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management


US FDA grants pediatric exclusivity to AstraZeneca's asthma inhaler

The U.S. FDA granted AstraZeneca PLC's Symbicort inhalation aerosol six months of pediatric exclusivity.

The decision was based on the evaluation of trials in children aged 6 to 12 years with asthma, in response to a written request by the company.

Symbicort is approved in the U.S. to treat asthma in patients 12 years and older. The inhaler is also approved for the maintenance treatment of chronic obstructive pulmonary disease in adults.